Loading search results

Outcome Measures

Primary Outcomes (1)

Overall Survival (OS)
Time from randomization to death from any cause. Patients not experiencing an event (i.e., patients alive at their individual end of study) will be censored with the last date the patient was known to be alive.
72 months

Secondary Outcomes (24)

Best response
72 months
Overall response rate (ORR)
72 months
Disease control rate (DCR)
72 months
Progression Free Survival (PFS)
72 months
Change from baseline in the global health scale score
72 months
+19 more secondary outcomes

Study Arms (2)

CANKADO (Arm A)

CANKADO application as eHealth support system: Patients use CANKADO for regular symptom self-reporting in addition to standard of care symptom management.

Other: eHealth system support for symptom management via CANKADO

Control (Arm B)

Control arm without eHealth support: Patients recieve standard of care symptom management.

Interventions

eHealth system support for symptom management via CANKADOOther

Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.

CANKADO (Arm A)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Eligible are patients with histologically or cytologically confirmed stage IV NSCLC or extensive-stage SCLC who have already been scheduled to receive first-line treatment with atezolizumab in combination with platinum-based chemotherapy induction followed by atezolizumab-containing maintenance therapy according to the German SmPC (Fachinformation) OR patients with advanced (locally advanced and inoperable or metastatic), PD-L1 IC-positive TNBC who have been scheduled for first-line treatment with atezolizumab in combination with nab-paclitaxel according to the German SmPC (Fachinformation).

You may qualify if:

Study Sites (92)

Onkologische Praxis im St. Marien-Krankenhaus

Ahaus, Germany

Gesundheitszentrum St. Marien

Amberg, Germany

Klinikum Arnsberg, Karolinen Hospital

Arnsberg, 59759, Germany

MVZ am Klinikum Aschaffenburg

Aschaffenburg, Germany

Klinikum Augsburg, II. Medizinische Klinik

Augsburg, 86156, Germany

Gemeinschaftspraxis Dr. Heinrich, Prof. Dr. Bangerter

Augsburg, Germany

Klinikum Bayreuth GmbH

Bayreuth, 95445, Germany

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaNeoplasm Metastasis

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (24)

Study Arms (2)

CANKADO (Arm A)

Control (Arm B)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (92)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (24)

Study Arms (2)

CANKADO (Arm A)

Control (Arm B)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (92)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations